The American Journal of Managed Care21h
How Access to SMA Treatment Varies Globally and by Insurance Type
Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic ...
Le Lézard5h
Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease
Merck , known as MSD outside of the United States and Canada, today announced that new clinical and outcomes research data will be presented at the American College of Cardiology's Annual Scientific ...
Sobi announces a new research collaboration on the development of Gamifant® (emapalumab) in sepsis, which is to be presented at the ISICEM congress
Sobi® (STO: SOBI), today announced a research collaboration involving a new Phase 2a clinical trial for Gamifant® (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS ...
The American Journal of Managed Care55m
EMBARK Data Show Continued Improvements With DMD Gene Therapy
Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that ...
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...
PharmiWeb6h
New data on investigational therapy for thymidine…
UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...